Conversely, a limited number of studies have linked decreased SHMT1 expression to the progression and poor prognosis of hepatocellular carcinoma and renal cell carcinoma, suggesting that SHMT may play dual roles as an oncogene or tumor suppressor, depending on the cellular context. This evidence concerns the gene SHMT2 and renal cell carcinoma.